Author:
Heist Rebecca S.,Sands Jacob,Bardia Aditya,Shimizu Toshio,Lisberg Aaron,Krop Ian,Yamamoto Noboru,Kogawa Takahiro,Al-Hashimi Saba,Fung Simon S.M.,Galor Anat,Pisetzky Francesca,Basak Priyanka,Lau Cindy,Meric-Bernstam Funda
Reference78 articles.
1. Potential of antibody-drug conjugates (ADCs) for cancer therapy;Marei;Cancer Cell Int,2022
2. Targeting cancer with antibody-drug conjugates: Promises and challenges;Dean;MAbs,2021
3. United States Food and Drug Administration. Full Prescribing Information: KADCYLA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf; 2023 [accessed March 25, 2023].
4. United States Food and Drug Administration. Full Prescribing Information: ELAHERE, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf; 2022 [accessed June 1, 2023].
5. United States Food and Drug Administration. Full prescribing information ENHERTU, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf; 2022 [accessed March 25, 2023].
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献